User profiles for Mark Stroh
Mark StrohCytomX Therapeutics, Inc. Verified email at cytomx.com Cited by 2845 |
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo
A solid tumor is an organ composed of cancer and host cells embedded in an extracellular
matrix and nourished by blood vessels. A prerequisite to understanding tumor …
matrix and nourished by blood vessels. A prerequisite to understanding tumor …
Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance
GM Kuziemko, M Stroh, RC Stevens - Biochemistry, 1996 - ACS Publications
The present study determines the affinity of cholera toxin for the ganglioside series GM1,
GM2, GM3, GD1A, GD1B, GT1B, asialo GM1, globotriosyl ceramide, and lactosyl ceramide …
GM2, GM3, GD1A, GD1B, GT1B, asialo GM1, globotriosyl ceramide, and lactosyl ceramide …
[PDF][PDF] A 'litmus test'for molecular recognition using artificial membranes
…, Q Cheng, A Reichert, G Kuziemko, M Stroh… - Chemistry & Biology, 1996 - cell.com
Background: Sensitive and selective molecular recognition is important throughout biology.
Certain organisms and toxins use specific binding at the cell surface as a first step towards …
Certain organisms and toxins use specific binding at the cell surface as a first step towards …
Incorporation of luminescent nanocrystals into monodisperse core–shell silica microspheres
Microspheres containing chromophores have been utilized in an extensive variety of
applications, including photonic crystals,[1, 2] biological labeling,[3, 4] and flow visualization in …
applications, including photonic crystals,[1, 2] biological labeling,[3, 4] and flow visualization in …
Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults
…, K Snyder, C Stevens, MA Stroh… - The Journal of …, 2007 - academic.oup.com
Context: The gastrointestinal peptide hormone, peptide YY 3–36 (PYY 3–36 ), is implicated
to be a postprandial satiety factor. Objective: The aim of this study is to assess the safety, …
to be a postprandial satiety factor. Objective: The aim of this study is to assess the safety, …
Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies
…, RE Sanborn, J Garcia-Corbacho, V Boni, M Stroh… - Clinical Cancer …, 2021 - AACR
Purpose: PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody–drug
conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. …
conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. …
Single‐dose administration of MK‐0657, an NR2B‐selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with …
C Addy, C Assaid, D Hreniuk, M Stroh… - The Journal of …, 2009 - Wiley Online Library
The glutamatergic system is thought to contribute to the motor disturbances observed in
Parkinson's disease. Blockade of glutamatergic activity by a selective antagonist of the NR2B …
Parkinson's disease. Blockade of glutamatergic activity by a selective antagonist of the NR2B …
A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non–small cell lung cancer based on early tumor kinetics
Purpose: Standard endpoints often poorly predict overall survival (OS) with immunotherapies.
We investigated the predictive performance of model-based tumor growth inhibition (TGI) …
We investigated the predictive performance of model-based tumor growth inhibition (TGI) …
[HTML][HTML] CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human …
…, G Durm, M Gil-Martin, M Stroh… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Probody® therapeutics are antibody prodrugs that are activated in the tumor
microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor …
microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor …
[HTML][HTML] Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopy
Neurotrophins such as nerve growth factor (NGF) may be useful for treating diseases in the
central nervous system; our ability to harness the potential therapeutic benefit of NGF is …
central nervous system; our ability to harness the potential therapeutic benefit of NGF is …